Colorectal liver metastasis has a high incidence, and RAS oncogene mutation status carries significant prognostic information. We aimed to assess whether RAS-mutated patients present more or less frequently with positive margins in their hepatic metastasectomy.
Methods
We performed a systematic review and meta-analysis of studies from PubMed, Embase, and Lilacs databases. We analyzed liver metastatic colorectal cancer studies, which included information on RAS status and had surgical margin analysis of the liver metastasis. Odds ratios were computed using a random-effect model due to anticipated heterogeneity. We further performed a subanalysis limited to studies that included only patients with KRAS instead of all-RAS mutations.
Results
From the 2,705 studies screened, 19 articles were included in the meta-analysis. There were 7,391 patients. The prevalence of positive resection margin was not significantly different between patients carrier vs non-carrier for the all-RAS mutations (OR .99; 95% CI 0.83-1.18; P = .87), and for only KRAS mutation (OR .93; 95% CI 0.73-1.19; P = .57).
Conclusions
Despite the strong correlation between colorectal liver metastasis prognosis and RAS mutation status, our meta-analysis’s results suggest no correlation between the RAS status and the prevalence of positive resection margins. The findings contribute to a better understanding of the RAS mutation’s role in the surgical resections of colorectal liver metastasis.
SungHFerlayJSiegelRL, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J Clin. 2021;71(3):209-249. DOI: 10.3322/caac.21660
2.
ZaydfudimVMMcMurryTLHarriganAM, et al.Improving treatment and survival: A population-based study of current outcomes after a hepatic resection in patients with metastatic colorectal cancer. HPB (Oxford). 2015;17. 10-24. Epub 2015 Sep 10. PMID: 26353888. doi:10.1111/hpb.12488
3.
SiegelRLMillerKDFuchsHEJemalA. Cancer statistics, 2022. CA A Cancer J Clin. 2022;72(1):7-33. Epub 2022 Jan 12. PMID: 35020204. doi:10.3322/caac.21708
CummingsLCPayesJDCooperGS. Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer. 2007;109(4):718-726. PMID: 17238180. doi:10.1002/cncr.22448
6.
FongYFortnerJSunRLBrennanMFBlumgartLH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg. 1999;230:309-318. discussion 318-21PMID: 10493478. doi:10.1097/00000658-199909000-00004
7.
AbdallaEKVautheyJNEllisLM, et al.Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:18-25. discussion 825-7PMID: 15166961. doi:10.1097/01.sla.0000128305.90650.71
8.
AbbasSLamVHollandsM. Ten-year survival after liver resection for colorectal metastases: Systematic review and meta-analysis. ISRN Oncol. 2011;2011:763245.
9.
TomlinsonJSJarnaginWRDeMatteoRP, et al.Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25(29):4575-4580. PMID: 17925551. doi:10.1200/JCO.2007.11.0833
10.
CadyBStoneMDMcDermottWVJr, et al.Technical and biological factors in disease-free survival after hepatic resection for colorectal cancer metastases. Arch Surg. 1992;127(5):561-568. ; discussion 568-9PMID: 1575626. doi:10.1001/archsurg.1992.01420050085011
11.
EkbergHTranbergKGAnderssonR, et al.Determinants of survival in liver resection for colorectal secondaries. Br J Surg. 1986;73(9):727-731. doi:10.1002/bjs.1800730917
12.
AreCGonenMZazzaliK, et al.The impact of margins on outcome after hepatic resection for colorectal metastasis. Ann Surg. 2007;246:295-300. PMID: 17667509. 10.1097/SLA.0b013e31811ea962
13.
DhirMLydenERWangASmithLMUllrichFAreC. Influence of margins on overall survival after hepatic resection for colorectal metastasis: A meta-analysis. Ann Surg. 2011;254(2):234-242. PMID: 21694583. doi:10.1097/SLA.0b013e318223c609
14.
VautheyJNZimmittiGKopetzSE, et al.RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013;258(4):619-626. ; discussion 626-7PMID: 24018645; PMCID: PMC3856211. doi:10.1097/SLA.0b013e3182a5025a
15.
MargonisGABuettnerSAndreatosN, et al.Anatomical resections improve disease-free survival in patients With KRAS-mutated colorectal liver metastases. Ann Surg. 2017;266(4):641-649. PMID: 28657938. doi:10.1097/SLA.0000000000002367
16.
MargonisGABuettnerSAndreatosN, et al.Association of BRAF Mutations With survival and recurrence in surgically treated patients with metastatic colorectal liver cancer. JAMA Surg. 2018;153:e180996.
17.
PollockCBShirasawaSSasazukiTKolchWDhillonAS. Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. Cancer Res. 2005;65(4):1244-1250. PMID: 15735008. doi:10.1158/0008-5472.CAN-04-1911
18.
TanCDuX. KRAS mutation testing in metastatic colorectal cancer. World J Gastroenterol. 2012;18:51-80. PMID: 23066310. doi:10.3748/wjg.v18.i37.5171
19.
BrudvikKWMiseYChungMH, et al.RAS mutation predicts positive resection margins and narrower resection margins in patients undergoing resection of colorectal liver metastases. Ann Surg Oncol. 2016;23(8):2635-2643. Epub 2016 Mar 25. PMID: 27016292; PMCID: PMC5527830. doi:10.1245/s10434-016-5187-2
20.
WongNAGonzalezDSalto-TellezM, et al.RAS testing of colorectal carcinoma—a guidance document from the association of clinical pathologists molecular pathology and diagnostics group. J Clin Pathol. 2014;67(9):751-757. PMID: 24996433. doi:10.1136/jclinpath-2014-202467
21.
YaegerRCowellEChouJF, et al.RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer. 2015;121:119-203. Epub 2014 Dec 9. PMID: 25491172. doi:10.1002/cncr.29196
22.
OdisioBCYamashitaSHuangSY, et al.Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status. Br J Surg. 2017;104:760-768. Epub 2017 Feb 27. PMID: 28240361. doi:10.1002/bjs.10490
23.
ShadyWPetreENVakianiE, et al.Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases. Oncotarget. 2017;8:66117-66127. PMID: 29029497. doi:10.18632/oncotarget.19806
24.
AmikuraKAkagiKOguraTTakahashiASakamotoH. The RAS mutation status predicts survival in patients undergoing hepatic resection for colorectal liver metastases: The results from a genetic analysis of all-RAS. J Surg Oncol. 2018;117(4):745-755. Epub 2017 Nov 30. PMID: 29194647. doi:10.1002/jso.24910
25.
BrudvikKWKopetzSELiLConradCAloiaTAVautheyJN. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg. 2015;102(10):1175-1183. Epub 2015 Jul 21. PMID: 26206254. doi:10.1002/bjs.9870
26.
MargonisGASpolveratoGKimYKaragkounisGChotiMAPawlikTM. Effect of KRAS mutation on long-term outcomes of patients undergoing hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2015;22(13):4158-4165. Epub 2015 Jun 16. PMID: 26077912. doi:10.1245/s10434-015-4587-z
27.
MargonisGAKimYSpolveratoG, et al.Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis. JAMA Surg. 2015;150:722. doi:10.1001/jamasurg.2015.0313
28.
SchirripaMBergamoFCremoliniC, et al.BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br J Cancer. 2015;112:1921. doi:10.1038/bjc.2015.142
29.
MargonisGASasakiKKimY, et al.Tumor biology rather than surgical technique dictates prognosis in colorectal cancer liver metastases. J Gastrointest Surg. 2016;20(11):1821-1829. Epub 2016 Jul 6. PMID: 27384430. doi:10.1007/s11605-016-3198-8
30.
Van CutsemECervAntesAAdamR, et al.ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386-1422. Epub 2016 Jul 5. PMID: 27380959. doi:10.1093/annonc/mdw235
31.
García-AlfonsoPGarcía-CarboneroRGarcía-FoncillasJ, et al.Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National consensus of the spanish society of medical oncology and the spanish society of pathology. Clin Transl Oncol. 2020;22:1976-1991. Epub 2020 May 16. PMID: 32418154. doi:10.1007/s12094-020-02357-z
32.
WellsGASheaBO’ConnellDPetersonJWelchVLososMTugwellP. The Newcastle-Ottawa Scale (NOS) for assessing the Quality of Nonrandomised Studies in Meta-analyses, 2022. Ottawa Hospital Research Institute. [Internet][cited 2022 July 25]. Available from:https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
33.
MoherDLiberatiATetzlaffJAltmanDGPRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009;6(7):e1000097. Epub 2009 Jul 21. PMID: 19621072; PMCID: PMC2707599. doi:10.1371/journal.pmed.1000097
34.
HatanoEOkunoMNakamuraK, et al.Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study). J Hepatobiliary Pancreat Sci. 2015;22(8):634-645. Epub 2015 Apr 29. PMID: 25926024. doi:10.1002/jhbp.254
35.
HattaAAZPathankiAMHodsonJ, et al.The effects of resection margin and KRAS status on outcomes after resection of colorectal liver metastases. HPB (Oxford). 2021;23(1):90-98. Epub 2020 May 13. PMID: 32417170. doi:10.1016/j.hpb.2020.04.016
36.
JoechleKVreelandTJVegaEA, et al.Anatomic resection is not required for colorectal liver metastases with RAS mutation. J Gastrointest Surg. 2020;24(5):1033-1039. Epub 2020 Mar 10. PMID: 32162236. doi:10.1007/s11605-019-04299-6
37.
KimHSLeeJMKimHS, et al.Prognosis of synchronous colorectal liver metastases after simultaneous curative-intent surgery according to primary tumor location and KRAS mutational status. Ann Surg Oncol. 2020;27(13):5150-5158. Epub 2020 Aug 18. PMID: 32812112. doi:10.1245/s10434-020-09041-0
38.
KobayashiSTakahashiSNomuraS, et al.BRAF V600E potentially determines “Oncological Resectability” for “Technically Resectable” colorectal liver metastases. Cancer Med. 2021;10:6998-7011. Epub 2021 Sep 18. PMID: 34535965. doi:10.1002/cam4.4227
39.
MoratóOVillamonteMSánchez-VelázquezP, et al.KRAS Assessment Following ESMO recommendations for colorectal liver metastases. is it always worth it?Healthcare (Basel). 2022;10:472. doi:10.3390/healthcare10030472
40.
MoroAMehtaRTsilimigrasDI, et al.Prognostic factors differ according to KRAS mutational status: A classification and regression tree model to define prognostic groups after hepatectomy for colorectal liver metastasis. Surgery. 2020;168(3):497-503. Epub 2020 Jul 13. PMID: 32675031. doi:10.1016/j.surg.2020.05.019
41.
O ConnorJMSanchez LoriaFArdilesV, et al.Prognostic impact of K-RAS mutational status and primary tumor location in patients undergoing resection for colorectal cancer liver metastases: an update. Future Oncol. 2019;15(27):3149-3157. Epub 2019 Aug 20. PMID: 31426677. doi:10.2217/fon-2019-0196
42.
ProcopioFViganòLCiminoMDonadonMDel FabbroDTorzilliG. Does KRAS mutation status impact the risk of local recurrence after R1 vascular resection for colorectal liver metastasis? An observational cohort study. Eur J Surg Oncol. 2020;46(5):818-824. Epub 2019 Dec 5. PMID: 31839435. doi:10.1016/j.ejso.2019.12.004
43.
SaadatLVBoernerTGoldmanDA, et al.Association of RAS mutation location and oncologic outcomes after resection of colorectal liver metastases. Ann Surg Oncol. 2020;28(2):817-825. Epub 2020 Jul 18. PMID: 32683635; PMCID: PMC7854850. doi:10.1245/s10434-020-08862-3
44.
SakaiNFurukawaKTakayashikiTKubokiSTakanoSOhtsukaM. Differential effects of KRAS mutational status on long-term survival according to the timing of colorectal liver metastases. BMC Cancer; 2021;21:412. doi:10.1186/s12885-021-08144-5
45.
ShindohJNishiokaYYoshiokaR, et al.KRAS mutation status predicts site-specific recurrence and survival after resection of colorectal liver metastases irrespective of location of the primary lesion. Ann Surg Oncol. 2016;23(6):1890-1896. Epub 2016 Jan 19. PMID: 26786089. doi:10.1245/s10434-016-5087-5
46.
TakedaYMiseYTakahashiY, et al.Limited prognostic value of KRAS in Patients undergoing hepatectomy for colorectal liver metastases. Ann Surg Oncol. 2022;29(4):2383-2391. Epub 2021 Dec 1. PMID: 34851437. doi:10.1245/s10434-021-11015-9
47.
TengHWHuangYCLinJK, et al.BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. J Surg Oncol. 2012;106(2):123-129. Epub 2012 Feb 13. PMID: 22331825. doi:10.1002/jso.23063
48.
YanXLWangKBaoQ, et al.Prognostic value of the combination of primary tumor location and RAS mutational status on patients with colorectal liver metastasis undergoing hepatectomy. J Surg Oncol. 2022;125(6):1002-1012. Epub 2022 Feb 16. PMID: 35171534. doi:10.1002/jso.26816
49.
ZhangQPengJYeM, et al.KRAS mutation predicted more mirometastases and closer resection margins in patients with colorectal cancer liver metastases. Ann Surg Oncol. 2020;27(4):1164-1173. Epub 2019 Nov 12. PMID: 31720935. doi:10.1245/s10434-019-08065-5
50.
ArringtonAKHeinrichELLeeW, et al.Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci. 2012;13(10):12153-12168. PMID: 23202889; PMCID: PMC3497263. doi:10.3390/ijms131012153
51.
DomingoERamamoorthyROukrifD, et al.Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. J Pathol. 2013;229(3):441-448. PMID: 23165447; PMCID: PMC3588155. doi:10.1002/path.4139
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
